Cytel other research news
CYTL has developed a new method for identifying peptides that can be used to develop therapeutic vaccines, according to research reported in Cell. The technology focuses on the role of secondary anchor residues in peptide binding to histocompatibility leukocyte antigen-A2.1 (HLA-A2.1) molecules. According to the company, it makes possible the efficient identification of the appropriate antigenic peptides responsible for invoking a disease-specific cytotoxic T cell response.
Starting with a whole viral or cancer protein, company scientists used proprietary algorithms to reduce the number of potential antigenic peptides to be synthesized and analyzed. The number of potential candidates was narrowed further using high throughput assays, after which in vitro and in vivo analysis was used to obtain the antigenic peptide best-suited for formulation. ...